Priority Program
Colonization and interaction of tumor cells in the bone microenvironment
News & Blog
Trials, tribulations and first break-throughs
Research requires flexibility and alternative strategies in order to succeed! Dr. Anne Offermann and Prof. Sven Perner, Universitätsklinikum Schleswig Holstein, Campus Lübeck and Leibniz Forschungszentrum Borstel [...]
How tumor cells manage oxygen during bone metastasis
by Diana Gaete, Martina Rauner and Ben Wielockx, TU Dresden And the Nobel Prize for Physiology or Medicine goes to… William Kaelin Jr., Peter Ratcliffe and Gregg Semenza" for [...]
2nd workshop on FACS in Erlangen
by Xia Pu, OncoRay Dresden Our second workshop “Dealing with Flow Cytometry (FCM)/Fluorescence-activated cell sorting (FACS)” and “Statistical fire instruction” has been carried out at the Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen. [...]
Towards a better understanding of bone metastasis
Cancer is one of the leading causes of death worldwide. Despite medical progress in the treatment of the primary tumor, most patients suffer and die from metastases at distant locations, such as bone. In contrast to most soft tissue metastases, bone metastases frequently lead to fractures, pain and a poor life quality.
Once established, bone metastases represent a point of no return and are rarely curable. They are even also regarded as a new source for systemic relapse. A better mechanistic understanding of this critical step of tumor progression is essential to target bone metastases, independent of the type of primary tumor.
The key steps of bone metastasis, including the initial colonization of bone by tumor cells and the early interaction with bone cells need to be better understood.
Thus, the fundamental questions
of our consortium are
To obtain mechanistic insights into these questions, the consortium focusses on breast and prostate cancer, reflecting the most common malignancies of women and men with a high propensity for bone metastases.
The µbone consortium will include myeloma bone disease as a prototypical malignant bone microenvironment disease to gain essential lateral insights into osteolytic bone lesions, which are a hallmark of myeloma. The researchers will jointly tackle the knowledge gap on bone metastases and reveal innovative mechanistic concepts of bone-tumor interactions (as a starting point) for subsequent studies to prevent or cure bone metastases.